Introduction
According to the National Gastric Cancer Registration Survey Report of 1984, early gastric cancer accounts for 36%of all gastric cancer cases, suggesting remarkable progress in the diagnosis of this malignancy (1) . Advanced gastric cancer represents the remaining 64%, and scirrhous gastric cancer accounts for about 15%of these cases. This type of cancer is well knownto be rapid growing and the early expression of its malignancy is still unclear even by the retrospective observation of radiological and endoscopic films recorded precedently (2, 3) , and the complication of cancerous peritonitis is often noted at the time of diagnosis (4) . The affliction of this cancer in youngwomenmaynot be infrequent, and the prognosis is extremely poor (5) . Even if scirrhous gastric cancer is macroscopically resected, peritoneal metastasis maybe present microscopically (with a high positivity rate in intraperitoneal free cancer cells and a high recurrence rate) (6) . In this sense, it may be inevitable to consider manycases of scirrhous gastric cancer to be beyond the point of benefit from surgical treatment.
Therefore, surgery combined with chemotherapy is necessary for the treatment of patients with scirrhous gastric cancer. With regard to chemotherapy for advanced gastric cancer, as reviewed by Leichman and Berry in 1991 (7) , cisplatin-based regimens have been widely adopted as the effective combinations, based on the experimental results ofSchabel et al in which cisplatin-combined chemotherapy has shown synergistic cytotoxicity against murine LI210 leukemia (8) Gastric Cancer Therapy modulation mechanism which would be later described more in detail (14, 15) .
Wealso present surgical results in a case in which UFT/ CDDP was administered in advance as a neoadjuvant chemotherapy, and examine the usefulness of this combined modality.
Patients and Methods
From The stomach is divided into three segments; upper (C), middle (M) and lower (A) third (17) . According to this classification, scirrhous gastric cancer occupied only one segment (M region) in one patient (4%), and she had the combination of peritoneal dissemination accompanying ascites. The cancer was located in two segments in seven patients (25%), including four (14%) with cancer affecting C and Mregions, and three (11%) affecting Mand A regions. All three regions were affected in 20 patients (71%). Ascites was noted in 13 patients (46%) at the first examination. They had no distant metastasis.
The histological type of the disease was signet ring cell carcinoma in 16 patients (57%), poorly differentiated carcinoma in seven (25 %) and moderately differentiated tubular adenocarcinoma in five (18%).
Chemotherapy (4, 18) Initially, UFT at a daily dose of400/m2 was orally administered, divided into two doses before breakfast and supper for 8 weeks, then UFT250/m was orally administered in the same manner after the first 8 weeks. CDDPwas administered 5 to 7 days after the start ofUFT treatment. CDDPat a dose of90 mg/ mwas reconstituted and administered in a mixture of 1 ,400 ml of 5% glucose solution and 1,400 of normal saline with 20 mEqKCLover 24 hours. CDDPtreatment was followed by reduced CDDPdose of 80 mg/m2/day for the second and third courses.
Patients received a mixture of 700 ml 5%-glucose and 700 ml normal saline with 10 mEqKCLby 12 hours continuous infusion given before and after each dose ofCDDP (Figs. 1 , 2 ).
To maximizethe benefits of long-term exposure of cisplatin, this drug was administered by 24-hour continuous intravenous infusion. In patients with the complication of cancerous peritonitis, however, 100 mg/body of cisplatin was directly injected into the peritoneum. Administration was performed at a frequency of once in four weeks, and repeated (two or) three times. Surgery was scheduled 3 to 4 weeks after the second (or third) cisplatin administration. In patients who continued chemotherapy without surgery, additional administration of CDDP80 mg/m2 was given at the time point at which re-exacerbation of cancerous lesions was observed or anticipated. Maximum numberof courses was five.
Hydration and diuresis (4, 18) To prevent nephrotoxicity induced by cisplatin, hydration and diuresis were performed before and after cisplatin administration, as shown in Fig. 2 . A mixture of700ml of5% glucose solution and 700 ml of physiological saline solution (with 10 mEqof KC1) was continuously infused for 12 hours starting from 13 hours before cisplatin administration, and, immediately thereafter, 200 (to 300) ml of 20% D-mannitol was intravenously infused over one hour (which was followed by 24-hour continuous intravenous infusion of cisplatin). For hydration after cisplatin administration, the above glucosesaline solution with added KC1was administered for one to three days to facilitate diuresis. About 3,000 ml and 2,000 ml (or more) of daily urine volume were secured on the day ofcisplatin administration, and the days before and after the administration, respectively. A 5HT3 receptor antagonist of serotonin (5-
UFT 400 mg/m2 t t * CDDP 90 mg/m2 80 mg/m2 80 mg/m2 Figure 1 . UFT/CDDPtherapy. Mixture ofuracil and tegafur in a 4:1 molar ratio (UFT) was given orally b.i.d., every day at a dose of400 mg/m2 for 8 weeks, then the daily dose ofUFT was reduced to 250 mg/m2. Cisplatin (CDDP) was administered by 24-hour infusion 5-7 days after the beginning ofUFT treatment and repeated every 4 weeks. The doses of CDDPfor the 2nd and 3rd course were reduced to 80 mg/m2. Figure 2 . Scheme ofUFT/CDDP therapy. Cisplatin was dissolved in 2,800 ml of physiological saline -5% glucose solution with 20 mEq KC1, and administered intravenously for 24 hours. Hydration and diuresis was also induced before and after cisplatin infusion, using 200 to 300 ml of20% D-mannitol. Antiemetic drugs such as granisetron was also given once or twice a day to prevent nausea and vomiting.
hydroxytryptamine; 5HT) was used to prevent emesis in the morning and evening of the day of cisplatin administration, and whenever necessary thereafter.
Surgical treatment
After two or three courses of chemotherapy, secondary treatment with total gastfectomy was performed in patients who exhibited improvement of primary foci, after informed consent had been obtained. The resected stomach was sliced into 5-mm sections, and subjected to histological examination for the purpose of identifying antitumor effects of the chemotherapy. Survival times were compared with those of 25 scirrhous gastric cancer patients who were treated surgically at the Department of Surgery of our hospital during the same period of time.
Ana lysis Tumorresponse rates were documentedaccording to the revised criteria for evaluating the efficacy of chemotherapy/ radiation therapy in the treatment of gastric cancer ( 1993) ( 19) .
Evaluation of chemotherapy
The revised criteria for evaluating the efficacy of chemotherapy/radiation therapy in the treatment of gastric cancer (1993) was used (19) . First, cancer lesions were visualized by barium filling method in the upright frontal position, showing narrowness of the involved area, due to diffusely infiltrating disease. With regard to scirrhous gastric cancer (diffusely infiltrating tumors), assessment of efficacy of chemotherapy was as follows: Complete response (CR) was defined as the disappearance of all tumors on X-ray films for a minimumof four weeks. Partial response (PR) was defined as a minimumof 50%enlargement of the involved area on X-ray films persisting for more than four weeks. No change (NC) was defined as aless than 50%enlargement for a minimumof four weeks. Progressive disease (PD) was defined as tumor progression detected by X-ray examination (19) . Regarding the assessment of histological efficacy of chemotherapy, in brief, the criteria was as follows: Grade 3; the disappearance, necrosis, and/or degeneration of total cancer, Grade 2; those changes of more than two-thirds cancer, Grade lb; those changes of one-third to two-thirds cancer, Grade la; those changes of less than one-third cancer, and Grade 0; almost no improvement of cancer (19) , Adverse reactions were recorded in compliance with the rules of the Japan Society for Cancer Therapy (20). The survival rate was calculated using the Kaplan-Meier methodfor the period from the initiation of treatment until February 1995.
Results
Overall response A total of 28 patients were accrued to this study. There were fourteen partial responses against the primary foci with an overall response rate of 50%. Among the 13 patients with cancerous peritonitis, ascites disappeared completely in eight (62%). Eleven patients (39%) showed no changes (NC) and three patients (10%) showed progressive disease (PD). Total gastrectomy was performed in ten patients after evaluation of response, including 7 PR, 2 NC and 1 PD patients. Median survival time of PR and non-PR (NC and PD) patients were 1 5. 1 months and 6.2 months, respectively. Mediansurvival time of all patients was 10. 1 months. The survival curves of patients are shown in Fig. 3 .
Response in surgical cases Total gastrectomy was performed in ten patients after two or three courses of chemotherapy. Regarding the effects of preoperative chemotherapy in 10 patients, 7 patients had PR, 2 patients had NCand one patient had PD. Palliative total gastrectomy was performed in the patient with PDupon request of the patient and the family. The degree ofhistological improvement in the resected gastric specimen was evaluated as Grade 2 in four patients, as reported in a previous paper (21, 22), Grade lb in three, Grade la in one and Grade 0 in two. Onthe basis of the Figure 4 . Survival period of patients treated by combined modality of UFT/CDDP chemotherapy with surgery or surgery alone. Combined modality of chemotherapy with surgery was feasible against scirrhous gastric cancer.
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Adversereactions
The most frequently reported toxicities were nausea and vomiting, anemia and leukopenia. There was no patient who experienced grade 4 toxicity. Grade 3 and Grade 2 leukopenia were shown in 3 and 9 patients, respectively. Grade 2 anemia were shown in 14 (50%) out of 28 patients. Renal and hepatic dysfunction were observed but reversible. However,patients with decreases in hemoglobin of Grade 2 (9.4-8.0 g/dl) and Grade 1 (10.9-9.5 g/dl) received concentrated erythrocyte transfusions.
Discussion
The scirrhous gastric cancer (Linitis plastica or Borrmann' s type 4) we have discussed in this article was defined as a diffuse advanced cancer with scirrhous invasion, which occupies more than one-third of the entire stomach, centering around the gastric body (23). According to the definition of Nakamura et al, it would be evaluated as "problematic scirrhous gastric cancer" (24). It is not a merely histological scirrhous gastric cancer such as those subclassified into Borrmann's type 3 or early cancer-like morphology. The depth of invasion was diagnosed as at least subserosal layer and/or exposure on the serosa (23). With respect to the results of surgical treatment of scirrhous gastric cancer, Ichikura and Tamakumareported a two-year cumulative survival rate of about 30%,a three-year of 20%(as determined from the survival curve) and a five-year of 1 0% in patients whose primary lesion invaded into the subserosal or deeper layers and surgical treatment resulted in curability of A or B (25). According to the results of surgical treatment reported by Furukawa et al (26) and Iwanaga et al (27) , two-, three-and five-year survival rates in patients treated with conventional total gastrectomy and pancreaticosplenic resection were about 30%, 10-20% and 10%, respectively. Among the patients treated with left upper abdominal evisceration (LUAE) and the Appleby extended operation (n=17), the twoto-four-year survival rate was about 50%(as determined from the survival curve) (26, 27). The results of surgical treatment, applied principally in our hospital with total gastrectomy and lymph node dissection, are not exactly as good as those of the above extended surgery (LUAE,etc.), even though the operation was limited to gastrectomy and lymph node dissection. In the present study, survival time and postoperative quality of life were also favorable, and therefore, preoperative, neoadjuvant chemotherapy was considered to have a significant value. With respect to preoperative chemotherapy for scirrhous gastric cancer, Mai et al applied sequential methotrexate 5-fluorouracil (MTX/5FU) therapy and other therapies, and reported their usefulness (28).
In this section, both experimental and clinical basis of UFT/ CDDPcombination chemotherapy must be given and the validity of the treatment would be assessed in relation to clinical results. First, UFT/CDDPtherapy avoids myelotoxicity by omitting adriamycin, mitomycin C, and epirubucin. Secondly, a long-term continuous intravenous infusion of 5-fluorouracil was replaced by an oral administration of UFTwith benefit of practical use. In addition to antitumor activity of cisplatin by forming DNAinterstrand crosslinks, the combination of UFT with cisplatin exerts synergistic inhibitory activity on DNA synthesis through dual biochemical modulation mechanism (15) Concerning the plasma level of 5-fluorouracil it was shown that the concentration (area under curve; AUC)was similar between continuous i.v. infusion of 5-fluorouracil 250 mg/m2 and UFT 400 mg/m2 orally daily (34, 35) . In regard to the combination of UFTand cisplatin, cisplatin promotes inhibition of DNAsynthesis by enhanced formation of reduced folate 5, 10-methylenetetrahydrofolate (CH2FH4), which makes a ternary complex with thymidylate synthase (TS) and 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), as already describedby Scanlon et al in 1986 ( 14) , andreconfirmed by Shirasaka et al in 1993 (15) . As for the administration schedule ofcisplatin alone, Drewinko et al showed in a L-1210 in vitro experiment that long-term continuous administration over 8 hours was more beneficial than short-term administration (36). Posner et al reported that clinically, 5-day continuous intravenous administration has been assumed to be superior to bolus administration (37). Lacave et al also adopted a 24-hour continuous intravenous infusion (1 1 ( 15) . We administered 80-100 mg/m2 ofcisplatin by continuous 24-hour intravenous infusion every 4 weeks along with the oral administration of UFTat a dose of 200 mg/m2 twice aday (4, 18) . In a previous trial, UFT/CDDP therapy was indicated for 20 patients with bulky advanced gastric cancers, and resulted in the response rate of80% ( 1 6/20) in primary lesions according to the revised efficacy criteria in 1993 (19) . Ascites due to peritoneal dissemination completely disappeared in seven out of 8 patients (88%). Myelotoxicity was mild except anemia. As can be seen Moreover, more complete lymph node dissection during the operation is expected to prolong survival times. Surgical treatment of patients with complicating peritoneal dissemination also remains as a future task (40). Most of all, development of chemotherapy with better efficacy is eagerly anticipated.
With regard to the conduction of chemotherapy, Yonemura et al demonstrated in 1993 that neoadjuvant chemotherapy using cisplatin/mitomycin C/UFT/etoposide (PMUE) achieved longer survival times than did postoperative adjuvant chemotherapy in the treatment of high-grade advanced gastric cancer (41). The results obtained from the present study should be confirmed by a randomized control study (phase III study) comparing preoperative UFT/CDDPand surgery alone. 
